EP2322216A1
(en)
|
1997-03-21 |
2011-05-18 |
Chugai Seiyaku Kabushiki Kaisha |
A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient
|
ATE387215T1
(en)
*
|
2000-10-25 |
2008-03-15 |
Chugai Pharmaceutical Co Ltd |
AGENT FOR PREVENTING OR TREATING PSORIASIS HAVING AN IL-6 ANTAGONIST AS THE ACTIVE INGREDIENT
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
US8840884B2
(en)
|
2002-02-14 |
2014-09-23 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing solution pharmaceuticals
|
US20060078533A1
(en)
*
|
2004-10-12 |
2006-04-13 |
Omoigui Osemwota S |
Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
|
GB2401040A
(en)
*
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
EP1673396A1
(en)
*
|
2003-09-22 |
2006-06-28 |
BioVation GmbH & Co.KG. |
Use of antibodies for reducing the biological effectiveness of il-6
|
MXPA06003768A
(en)
|
2003-10-17 |
2006-06-23 |
Chugai Pharmaceutical Co Ltd |
Therapeutic agent for mesothelioma.
|
US8617550B2
(en)
*
|
2003-12-19 |
2013-12-31 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment of vasculitis with IL-6 antagonist
|
EP3269738A1
(en)
|
2004-03-24 |
2018-01-17 |
Chugai Seiyaku Kabushiki Kaisha |
Subtypes of humanized antibody against interleukin-6 receptor
|
AR048335A1
(en)
|
2004-03-24 |
2006-04-19 |
Chugai Pharmaceutical Co Ltd |
THERAPEUTIC AGENTS FOR INTERNAL EAR DISORDERS CONTAINING AN IL-6 ANTAGONIST AS AN ACTIVE INGREDIENT
|
US20070036788A1
(en)
*
|
2004-09-22 |
2007-02-15 |
Ahmed Sheriff |
Use of a compound for reducing the biological effectiveness of il-6
|
PE20061324A1
(en)
*
|
2005-04-29 |
2007-01-15 |
Centocor Inc |
ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES
|
CA2625773C
(en)
*
|
2005-10-14 |
2015-05-12 |
Fukuoka University |
Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
|
RU2450830C2
(en)
*
|
2005-10-21 |
2012-05-20 |
Чугаи Сейяку Кабусики Кайся |
Agent for cardiopathy
|
AR057582A1
(en)
*
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES
|
US8771686B2
(en)
*
|
2006-01-27 |
2014-07-08 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for treating a disease involving choroidal neovascularization by administering an IL-6 receptor antibody
|
JP5624276B2
(en)
|
2006-03-31 |
2014-11-12 |
中外製薬株式会社 |
Methods for controlling blood kinetics of antibodies
|
JP5754875B2
(en)
*
|
2006-04-07 |
2015-07-29 |
国立大学法人大阪大学 |
Muscle regeneration promoter
|
US8080248B2
(en)
|
2006-06-02 |
2011-12-20 |
Regeneron Pharmaceuticals, Inc. |
Method of treating rheumatoid arthritis with an IL-6R antibody
|
EP2041177B1
(en)
|
2006-06-02 |
2011-12-14 |
Regeneron Pharmaceuticals, Inc. |
High affinity antibodies to human il-6 receptor
|
MX2009001110A
(en)
|
2006-08-03 |
2009-05-11 |
Vaccinex Inc |
Anti-il-6 monoclonal antibodies and uses thereof.
|
ES2564392T3
(en)
*
|
2007-01-23 |
2016-03-22 |
Shinshu University |
IL-6 inhibitors for the treatment of chronic rejection
|
US8252286B2
(en)
|
2007-05-21 |
2012-08-28 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat thrombosis
|
EP2162469A4
(en)
*
|
2007-05-21 |
2012-08-01 |
Alderbio Holdings Llc |
Novel rabbit antibody humanization methods and humanized rabbit antibodies
|
US8178101B2
(en)
|
2007-05-21 |
2012-05-15 |
Alderbio Holdings Inc. |
Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
|
US9701747B2
(en)
|
2007-05-21 |
2017-07-11 |
Alderbio Holdings Llc |
Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
|
US7906117B2
(en)
*
|
2007-05-21 |
2011-03-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
|
US20090238825A1
(en)
*
|
2007-05-21 |
2009-09-24 |
Kovacevich Brian R |
Novel rabbit antibody humanization methods and humanized rabbit antibodies
|
US8062864B2
(en)
*
|
2007-05-21 |
2011-11-22 |
Alderbio Holdings Llc |
Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
|
US8404235B2
(en)
*
|
2007-05-21 |
2013-03-26 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
NZ597767A
(en)
|
2007-05-21 |
2013-06-28 |
Bristol Myers Squibb Co |
Antibodies to IL-6 and use thereof
|
HUE029635T2
(en)
|
2007-09-26 |
2017-03-28 |
Chugai Pharmaceutical Co Ltd |
Method of modifying isoelectric point of antibody via amino acid substitution in cdr
|
MY163473A
(en)
|
2007-09-26 |
2017-09-15 |
Chugai Pharmaceutical Co Ltd |
Modified antibody constant region
|
PE20091174A1
(en)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
|
TW202423982A
(en)
|
2008-04-11 |
2024-06-16 |
日商中外製藥股份有限公司 |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
DK2297202T3
(en)
|
2008-05-13 |
2016-03-21 |
Novimmune Sa |
ANTI-IL-6 / IL-6R ANTIBODIES AND PROCEDURES FOR USE THEREOF
|
WO2009148148A1
(en)
*
|
2008-06-05 |
2009-12-10 |
国立がんセンター総長が代表する日本国 |
Neuroinvasion inhibitor
|
US8188235B2
(en)
|
2008-06-18 |
2012-05-29 |
Pfizer Inc. |
Antibodies to IL-6 and their uses
|
WO2010033635A1
(en)
*
|
2008-09-17 |
2010-03-25 |
Shocking Technologies, Inc. |
Voltage switchable dielectric material containing boron compound
|
TWI440469B
(en)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
US8323649B2
(en)
|
2008-11-25 |
2012-12-04 |
Alderbio Holdings Llc |
Antibodies to IL-6 and use thereof
|
US9452227B2
(en)
*
|
2008-11-25 |
2016-09-27 |
Alderbio Holdings Llc |
Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
|
US8992920B2
(en)
|
2008-11-25 |
2015-03-31 |
Alderbio Holdings Llc |
Anti-IL-6 antibodies for the treatment of arthritis
|
US8337847B2
(en)
|
2008-11-25 |
2012-12-25 |
Alderbio Holdings Llc |
Methods of treating anemia using anti-IL-6 antibodies
|
US8420089B2
(en)
|
2008-11-25 |
2013-04-16 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
US9212223B2
(en)
|
2008-11-25 |
2015-12-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat thrombosis
|
SI2493922T1
(en)
|
2009-10-26 |
2017-06-30 |
F. Hoffmann-La Roche Ag |
Method for the production of a glycosylated immunoglobulin
|
US9775921B2
(en)
|
2009-11-24 |
2017-10-03 |
Alderbio Holdings Llc |
Subcutaneously administrable composition containing anti-IL-6 antibody
|
KR20120118088A
(en)
|
2009-11-24 |
2012-10-25 |
앨더바이오 홀딩스 엘엘씨 |
Antibodies to il-6 and use thereof
|
JO3417B1
(en)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
|
SI2578231T1
(en)
|
2010-05-28 |
2023-01-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antitumor t cell response enhancer
|
KR20220070586A
(en)
|
2010-11-08 |
2022-05-31 |
제넨테크, 인크. |
Subcutaneously administered anti-il-6 receptor antibody
|
WO2012071561A2
(en)
|
2010-11-23 |
2012-05-31 |
Alder Biopharmaceuticals, Inc. |
Anti-il-6 antibodies for the treatment of anemia
|
KR102568454B1
(en)
|
2010-11-30 |
2023-08-18 |
추가이 세이야쿠 가부시키가이샤 |
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
|
WO2012101253A1
(en)
|
2011-01-28 |
2012-08-02 |
Sanofi |
Pharmaceutical compositions comprising human antibodies to pcsk9
|
AR087305A1
(en)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES, PREPARATION METHOD AND KIT
|
TWI589299B
(en)
|
2011-10-11 |
2017-07-01 |
再生元醫藥公司 |
Compositions for the treatment of rheumatoid arthritis and methods of using same
|
WO2013176471A1
(en)
|
2012-05-21 |
2013-11-28 |
한국생명공학연구원 |
Pharmaceutical composition for preventing or treating stat3-mediated disease, comprising salvia plebeia r. br. extract or fraction thereof as active ingredient
|
EP3009518B1
(en)
|
2013-06-11 |
2020-08-12 |
National Center of Neurology and Psychiatry |
Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
|
MX363403B
(en)
|
2013-07-04 |
2019-03-22 |
Hoffmann La Roche |
Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples.
|
WO2015054293A1
(en)
*
|
2013-10-07 |
2015-04-16 |
Alder Biopharmaceuticals, Inc. |
Anti-il-6 antibodies for the treatment of psoriatic arthritis
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
KR101892883B1
(en)
|
2015-02-27 |
2018-10-05 |
추가이 세이야쿠 가부시키가이샤 |
Composition for treating il-6-related diseases
|
ES2888801T3
(en)
|
2015-05-19 |
2022-01-07 |
Nat Center Neurology & Psychiatry |
Method to determine the application of a new therapy in patients with multiple sclerosis (MS)
|
MA42657A
(en)
|
2015-08-18 |
2018-06-27 |
Regeneron Pharma |
ANTI-PCSK9 ANTIBODY INHIBITORS FOR THE TREATMENT OF PATIENTS WITH HYPERLIPIDEMIA SUBJECTING LIPOPROTEIN APHERESIS
|
US11484591B2
(en)
|
2016-02-22 |
2022-11-01 |
Ohio State Innovation Foundation |
Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
|
AU2018234844B2
(en)
|
2017-03-17 |
2024-01-25 |
Ohio State Innovation Foundation |
Nanoparticles for delivery of chemopreventive agents
|
WO2018203545A1
(en)
|
2017-05-02 |
2018-11-08 |
国立研究開発法人国立精神・神経医療研究センター |
Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils
|
US11692037B2
(en)
|
2017-10-20 |
2023-07-04 |
Hyogo College Of Medicine |
Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
|
KR20200083538A
(en)
*
|
2017-11-29 |
2020-07-08 |
더 락커펠러 유니버시티 |
Combination of local and systemic therapy to improve the treatment of skin conditions
|
JP7542543B2
(en)
|
2019-01-31 |
2024-08-30 |
サノフィ・バイオテクノロジー |
Anti-IL-6 receptor antibodies for treating juvenile idiopathic arthritis - Patents.com
|
EP3947737A2
(en)
|
2019-04-02 |
2022-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|